ADC Therapeutics SA (ADCT) FinancialsADCTFinancialADC Therapeutics SA

ADC Therapeutics SA (ADCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 96.8% of total sales, equivalent to $18.63M. Other significant revenue streams include Royalties and Royalty Revenue. Understanding this composition is critical for investors evaluating how ADCT navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, ADC Therapeutics SA maintains a gross margin of 88.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -117.25%, while the net margin is -86.06%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ADCT converts its operational activities into shareholder value.

In the context of the broader market, ADCT competes directly with industry leaders such as MIST and CNTB. With a market capitalization of $142.99M, it holds a significant position in the sector. When comparing efficiency, ADCT's gross margin of 88.68% stands against MIST's 94.12% and CNTB's 100.00%. Such benchmarking helps identify whether ADC Therapeutics SA is trading at a premium or discount relative to its financial performance.

ADC Therapeutics reported a gross margin of 88.68% for Q2 2026, indicating strong profitability on sales despite overall losses. The company has also shown revenue growth, with Q2 2026 net product revenue at $18.6 million, up from $18.1 million year-over-year.